CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cogswell, J. P.
Right arrow Articles by Neill, S. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cogswell, J. P.
Right arrow Articles by Neill, S. D.
Cell Growth & Differentiation Vol. 11, 615-623, December 2000
© 2000 American Association for Cancer Research


Articles

Dominant-Negative Polo-like Kinase 1 Induces Mitotic Catastrophe Independent of cdc25C Function

John P. Cogswell1, Chadwick E. Brown, John E. Bisi and Suzanne D. Neill

Department of Functional Genetics, Glaxo Wellcome Inc., Research Triangle Park, North Carolina 27709

Abstract

Polo-like kinase 1 (PLK1), which has been shown to have a critical role in mitosis, is one possible target for cancer therapeutic intervention. PLK1, at least in Xenopus, starts the mitotic cascade by phosphorylating and activating cdc25C phosphatase. Also, loss of PLK1 function has been shown to induce mitotic catastrophe in a HeLa cervical carcinoma cell line but not in normal Hs68 fibroblasts. We wanted to understand whether the selective mitotic catastrophe in HeLa cells could be extended to other tumor types, and, if so, whether it could be attributable to a tumor-specific loss of dependence on PLK1 for cdc25C activation. When PLK1 function was blocked through adenovirus delivery of a dominant-negative gene, we observed tumor-selective apoptosis in most tumor cell lines. In some lines, dominant-negative PLK1 induced a mitotic catastrophe similar to that published in HeLa cells (K. E. Mundt et al., Biochem. Biophys Res. Commun., 239: 377–385, 1997). Normal human mammary epithelial cells, although arrested in mitosis, appeared to escape the loss of centrosome maturation and mitotic catastrophe seen in tumor lines. Mitotic phosphorylation of cdc25C and activation of cdk1 was blocked by dominant-negative PLK1 in human mammary epithelial cells as well as in the tumor lines regardless of whether they underwent mitotic catastrophe. These data strongly argue that the mitotic catastrophe is not attributable to a lack of dependence for PLK1 in activating cdc25C.




This article has been cited by other articles:


Home page
Cancer Res.Home page
J. Triscott, C. Lee, C. Foster, B. Manoranjan, M. R. Pambid, R. Berns, A. Fotovati, C. Venugopal, K. O'Halloran, A. Narendran, et al.
Personalizing the Treatment of Pediatric Medulloblastoma: Polo-like Kinase 1 as a Molecular Target in High-Risk Children
Cancer Res., November 15, 2013; 73(22): 6734 - 6744.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D.-C. Lin, Y. Zhang, Q.-J. Pan, H. Yang, Z.-Z. Shi, Z.-H. Xie, B.-S. Wang, J.-J. Hao, T.-T. Zhang, X. Xu, et al.
PLK1 Is Transcriptionally Activated by NF-{kappa}B during Cell Detachment and Enhances Anoikis Resistance through Inhibiting {beta}-Catenin Degradation in Esophageal Squamous Cell Carcinoma
Clin. Cancer Res., July 1, 2011; 17(13): 4285 - 4295.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Y. Degenhardt and T. Lampkin
Targeting Polo-like Kinase in Cancer Therapy
Clin. Cancer Res., January 15, 2010; 16(2): 384 - 389.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. G. Gilmartin, M. R. Bleam, M. C. Richter, S. G. Erskine, R. G. Kruger, L. Madden, D. F. Hassler, G. K. Smith, R. R. Gontarek, M. P. Courtney, et al.
Distinct Concentration-Dependent Effects of the Polo-like Kinase 1-Specific Inhibitor GSK461364A, Including Differential Effect on Apoptosis
Cancer Res., September 1, 2009; 69(17): 6969 - 6977.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
H. Yim and R. L. Erikson
Polo-Like Kinase 1 Depletion Induces DNA Damage in Early S Prior to Caspase Activation
Mol. Cell. Biol., May 15, 2009; 29(10): 2609 - 2621.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
V. Sherwood, R. Manbodh, C. Sheppard, and A. D. Chalmers
RASSF7 Is a Member of a New Family of RAS Association Domain-containing Proteins and Is Required for Completing Mitosis
Mol. Biol. Cell, April 1, 2008; 19(4): 1772 - 1782.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
L. M. Leoni, B. Bailey, J. Reifert, H. H. Bendall, R. W. Zeller, J. Corbeil, G. Elliott, and C. C. Niemeyer
Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating Agents
Clin. Cancer Res., January 1, 2008; 14(1): 309 - 317.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
F. Stegmeier, M. E. Sowa, G. Nalepa, S. P. Gygi, J. W. Harper, and S. J. Elledge
The tumor suppressor CYLD regulates entry into mitosis
PNAS, May 22, 2007; 104(21): 8869 - 8874.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
T. J. Lansing, R. T. McConnell, D. R. Duckett, G. M. Spehar, V. B. Knick, D. F. Hassler, N. Noro, M. Furuta, K. A. Emmitte, T. M. Gilmer, et al.
In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1
Mol. Cancer Ther., February 1, 2007; 6(2): 450 - 459.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
B. Spankuch, S. Heim, E. Kurunci-Csacsko, C. Lindenau, J. Yuan, M. Kaufmann, and K. Strebhardt
Down-regulation of Polo-like Kinase 1 Elevates Drug Sensitivity of Breast Cancer Cells In vitro and In vivo
Cancer Res., June 1, 2006; 66(11): 5836 - 5846.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
W. Malorni and C. Fiorentini
Is the Rac GTPase-activating toxin CNF1 a smart hijacker of host cell fate?
FASEB J, April 1, 2006; 20(6): 606 - 609.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E. Y. Chuang, X. Chen, M.-H. Tsai, H. Yan, C.-Y. Li, J. B. Mitchell, H. Nagasawa, P. F. Wilson, Y. Peng, M. M. Fitzek, et al.
Abnormal Gene Expression Profiles in Unaffected Parents of Patients with Hereditary-Type Retinoblastoma
Cancer Res., April 1, 2006; 66(7): 3428 - 3433.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
M. R. Bhonde, M.-L. Hanski, J. Budczies, M. Cao, B. Gillissen, D. Moorthy, F. Simonetta, H. Scherubl, M. Truss, C. Hagemeier, et al.
DNA Damage-induced Expression of p53 Suppresses Mitotic Checkpoint Kinase hMps1: THE LACK OF THIS SUPPRESSION IN p53MUT CELLS CONTRIBUTES TO APOPTOSIS
J. Biol. Chem., March 31, 2006; 281(13): 8675 - 8685.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
F. Eckerdt, J. Yuan, K. Saxena, B. Martin, S. Kappel, C. Lindenau, A. Kramer, S. Naumann, S. Daum, G. Fischer, et al.
Polo-like Kinase 1-mediated Phosphorylation Stabilizes Pin1 by Inhibiting Its Ubiquitination in Human Cells
J. Biol. Chem., November 4, 2005; 280(44): 36575 - 36583.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. Guan, P. Tapang, J. D. Leverson, D. Albert, V. L. Giranda, and Y. Luo
Small Interfering RNA-Mediated Polo-Like Kinase 1 Depletion Preferentially Reduces the Survival of p53-Defective, Oncogenic Transformed Cells and Inhibits Tumor Growth in Animals
Cancer Res., April 1, 2005; 65(7): 2698 - 2704.
[Abstract] [Full Text] [PDF]


Home page
aacredbookHome page
R. A. Mook Jr.
The Importance and Complexities of Target Class Selectivity in Drug Discovery
Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 223 - 226.
[Full Text] [PDF]


Home page
J Biol ChemHome page
L. Tsvetkov and D. F. Stern
Interaction of Chromatin-associated Plk1 and Mcm7
J. Biol. Chem., March 25, 2005; 280(12): 11943 - 11947.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
R. W. Gunawardena, H. Siddiqui, D. A. Solomon, C. N. Mayhew, J. Held, S. P. Angus, and E. S. Knudsen
Hierarchical Requirement of SWI/SNF in Retinoblastoma Tumor Suppressor-mediated Repression of Plk1
J. Biol. Chem., July 9, 2004; 279(28): 29278 - 29285.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
P. J. Gray Jr, D. J. Bearss, H. Han, R. Nagle, M.-S. Tsao, N. Dean, and D. D. Von Hoff
Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer
Mol. Cancer Ther., May 1, 2004; 3(5): 641 - 646.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
Y.-S. Seong, K. Kamijo, J.-S. Lee, E. Fernandez, R. Kuriyama, T. Miki, and K. S. Lee
A Spindle Checkpoint Arrest and a Cytokinesis Failure by the Dominant-negative Polo-box Domain of Plk1 in U-2 OS Cells
J. Biol. Chem., August 30, 2002; 277(35): 32282 - 32293.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Yuan, A. Kramer, F. Eckerdt, M. Kaufmann, and K. Strebhardt
Efficient Internalization of the Polo-Box of Polo-like Kinase 1 Fused to an Antennapedia Peptide Results in Inhibition of Cancer Cell Proliferation
Cancer Res., August 1, 2002; 62(15): 4186 - 4190.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 2000 by the American Association of Cancer Research.